REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/09/2025
Back to search
Official data from USPTO
ENZYVANT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
06/10/2025
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
03/07/2019
Registration date
06/09/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/09/2020
Last transaction
06/10/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
99
Owner location
Basel, CH
Examiner
AVENT, TEAGUE
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a design of ovals forming two concentric circles with the wording "ENZYVANT" appearing to the right of the design.
Holders and representatives
Holders
Enzyvant Therapeutics GmbH
Representatives
Allison Strickland Ricketts Fross Zelnick Lehrman & Zissu, P.C.
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for human use for the treatment of rare or metabolicacid ceramidase deficiencypediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto; pharmaceutical preparations for human usetissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of rare or metabolicacid ceramidase deficiencypediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto; biologic preparations for medical and therapeutic purposestissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseasesdisorders and conditionsimmune deficiency related thereto
Class 42
Scientific and technological servicesmedical researchscientific research and analysis in the fields of pharmaceuticals and biomedicine; pharmaceuticalbiomedical and biological therapeutic research services; scientific research in the fields of pharmaceutical and biologic therapeutic preparationsclinical trials and post-market clinical trials; pharmaceutical research and development; providing scientific research information in the fields of pharmaceuticalsbiomedicineclinical trials and post-market clinical trials
Class 44
Providing health and medical information; providing information relating to the diagnosticprophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseasesdisorders and conditions
Publications
History of USPTO decisions and trademark events.
26 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/09/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/24/2020
PUBO
PUBLISHED FOR OPPOSITION
03/24/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/04/2020
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/19/2020
ALIE
ASSIGNED TO LIE
02/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/31/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/31/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/27/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/26/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
01/26/2020
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/25/2020
GNFR
FINAL REFUSAL E-MAILED
01/25/2020
CNFR
FINAL REFUSAL WRITTEN
01/25/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/14/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/13/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/13/2019
DOCK
ASSIGNED TO EXAMINER
07/25/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/18/2019
GNRT
NON-FINAL ACTION E-MAILED
05/18/2019
CNRT
NON-FINAL ACTION WRITTEN
05/18/2019
DOCK
ASSIGNED TO EXAMINER
05/09/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
03/27/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/26/2019
NWAP
NEW APPLICATION ENTERED
03/11/2019
Continuous trademark protection
Get notified about every new filing that threatens ENZYVANT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.